ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

All Content

In this interview we discuss a recent study that found that more than half of patients with locally advanced cervical cancer in the United States did not receiving standard of care.

The addition of clofarabine to standard induction therapy for newly diagnosed acute myeloblastic leukemia reduced the probably of relapse but increased toxicity and had no effect on survival.

Here we review the role of interim PET/CT in diffuse large B-cell lymphoma (DLBCL), and also explore the question of whether new approaches to quantitative assessment improve the prognostic value of interim PET scans in both Hodgkin lymphoma and DLBCL.

Unfortunately, while survival outcomes with novel therapies have improved, the fraction of patients with multiple myeloma who are cured of their disease remains low. Immune therapies offer the hope for further improvement in outcomes and higher rates of cure.

Here we outline the most promising novel cellular immune strategies for patients with multiple myeloma. In addition, we highlight combinatorial approaches that, it is hoped, will further optimize cellular immunotherapies for myeloma and lead to deep and durable responses and, possibly, even cures.

Cancer patients are often referred for cachexia intervention treatments late in their disease trajectory—that is, at a point where attempts to reverse the weight loss process may be less beneficial. In addition, healthcare professionals frequently under-recognize the prevalence of cancer cachexia, and this may contribute to delayed treatment of weight loss, often until the refractory stage.

Despite consensus on the diagnosis and staging of cancer anorexia/cachexia syndrome, there is currently no accepted standard of care, and affected patients remain widely undertreated.

In this interview we discuss what needs to change in order to combat the negative health impact of tobacco use and what academic institutions and researchers can do to diminish the use of tobacco products.

It is challenging to diagnose, manage, and treat patients who have kidney disease in addition to cancer. Second to cardiovascular disease, cancer represents a major cause of mortality and morbidity in the kidney disease population.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.